DX Medical

DX Medical Solutions, operating under the name Diagnostix.AI, is a health-tech entity founded in 2019 by Giuliano Senese and Peter Velthuis. The company is headquartered in Amsterdam, Netherlands, with an operational office in Rome, Italy. Founder Giuliano Senese brought previous entrepreneurial experience to the venture from the sale of a prior company, 'Time Table'. The firm directs its efforts towards the development of differential-diagnosis tools for the healthcare sector, specifically targeting hospitals and clinical settings.

The company's core offering, Diagnostix, combines a proprietary or licensed protein analyzer for rapid blood tests with artificial intelligence software. This system analyzes micro blood samples along with a patient's preliminary work-up, including clinical history and symptoms, to suggest a potential diagnosis. The AI algorithm leverages a vast internal database, reportedly containing over one billion entries of epidemiological data, to identify patterns and predict diagnoses. By cross-referencing patient data with demographic and epidemiological statistics, the platform aims to provide a more specific and sensitive diagnostic assessment to assist physicians. This B2B model is designed to integrate into hospital workflows, providing a tool to accelerate diagnostic processes.

Since its inception, DX Medical Solutions has secured significant venture capital. A pre-seed round in October 2019 raised $500K, followed by a seed round of over $3.3 million in August 2020, led by Biofund and supplemented by government funding. Total funding has reached at least $3.8 million. A key milestone was a deal secured with the Dutch government for clinical trials in at least 20 public hospitals by early 2021. The company's business model appears to be centered on providing its diagnostic system to healthcare institutions, likely on a subscription or fee-per-use basis, to enhance clinical efficiency and diagnostic accuracy.

Keywords: DX Medical Solutions, Diagnostix.AI, health-tech, medical diagnostics, artificial intelligence, machine learning, differential diagnosis, Giuliano Senese, Peter Velthuis, blood test analyzer, epidemiological data, clinical decision support, diagnostic software, predictive diagnosis, venture capital, Biofund, healthcare AI, protein analyzer, medical data analysis, hospital technology